Redeye retains its positive view of Avensia despite a softer Q2 than expected. Low utilization rates hurt Sales-COGS/working day/employee, and EBIT. However, the utilization rate increased gradually during Q2, although remaining below normal levels. While we will likely somewhat lower our forecasts and Base Case, we believe the long-term case is intact.